(NVO) Novo Nordisk’s N9-GP See Positive Test Results

Novo Nordisk (NVO) recently announced positive phase III data on its hemophilia B candidate, N9-GP, from the paradigm 2 study. Paradigm 2 evaluated N9-GP, a long-acting FIX derivative, for on-demand or prophylactic treatment of hemophilia B patients. Results indicated that the once-weekly prophylactic administration of N9-GP could lower the risk of bleeds by more than 90% compared to on-demand treatment. Moreover, 99% of the few occurring bleeds could be stopped with a single dose The paradigm program includes 7 studies evaluating the pharmacokinetics, immunogenicity, efficacy and safety of N9-GP in adult and pediatric hemophilia B patients as well as in patients undergoing surgery. In the coming twelve months, Novo Nordisk expects the two remaining phase III studies in the paradigm program to be completed. N9-GP is expected to be filed […]